Shinzo Hiroi

Pharmacotherapy of type 2 diabetes: An update

Complementing Insulin Therapy to Achieve Glycemic Control

ROS in cancer therapy: the bright side of the moon

Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis

Trends in GPCR drug discovery: new agents, targets and indications

Influence of Continuous or Reciprocating Motion on Cyclic Fatigue Resistance of 4 Different Nickel-Titanium Rotary Instruments

Type 2 diabetes

Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

Safety, Efficacy, and Bioavailability of Fixed-Dose Combinations in Type 2 Diabetes Mellitus: A Systematic Updated Review

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease

Efficacy and safety of fasiglifam ( TAK ‐875), a G protein‐coupled receptor 40 agonist, in J apanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double‐blind, placebo‐controlled, phase III trial

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas

NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis

Nanotechnology for Multimodal Synergistic Cancer Therapy

The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis

The safety of dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis

[Advantages and limits of nickel-titanium instruments for root canal preparation. A review of the current literature].

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial with an open‐label long‐term extension study

GPR40‐induced insulin secretion by the novel agonist TAK‐875: first clinical findings in patients with type 2 diabetes

Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension

Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study

Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

Evaluation of the bioequivalence of a fixed-dose combination tablet of pioglitazone–metformin versus commercial tablets in healthy Japanese male volunteers